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Jens Flensted Lassen1, Per Thayssen3, Lisette Okkels Jensen3, Hans-Henrik Tilsted4 and Michael Maeng1*Abstract
Background: The impact of adherence to the recommended duration of dual antiplatelet therapy after first
generation drug-eluting stent implantation is difficult to assess in real-world settings and limited data are available.
Methods: We followed 4,154 patients treated with coronary drug-eluting stents in Western Denmark for 1 year and
obtained data on redeemed clopidogrel prescriptions and major adverse cardiovascular events (MACE, i.e., cardiac
death, myocardial infarction, or stent thrombosis) from medical databases.
Results: Discontinuation of clopidogrel within the first 3 months after stent implantation was associated with a
significantly increased rate of MACE at 1-year follow-up (hazard ratio (HR) 2.06; 95% confidence interval (CI):
1.08-3.93). Discontinuation 3-6 months (HR 1.29; 95% CI: 0.70-2.41) and 6-12 months (HR 1.29; 95% CI: 0.54-3.07)
after stent implantation were associated with smaller, not statistically significant, increases in MACE rates. Among
patients who discontinued clopidogrel, MACE rates were highest within the first 2 months after discontinuation.
Conclusions: Discontinuation of clopidogrel was associated with an increased rate of MACE among patients
treated with drug-eluting stents. The increase was statistically significant within the first 3 months after drug-eluting stent
implantation but not after 3 to 12 months.
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Dual antiplatelet therapy (DAPT), i.e., aspirin in com-
bination with a P2Y12 antagonist, has been shown to
reduce occurrence of ischemic events after coronary
stent implantation in randomized clinical trials [1,2]. In
real-world settings, however, the level of adherence to
recommended DAPT is difficult to assess and its influ-
ence on outcomes is less well known. Moreover, the
optimal duration of DAPT after coronary stent implan-
tation is disputed [3].
Twelve months of DAPT after percutaneous coronary
intervention (PCI) with coronary stent implantation
has been recommended in Denmark since November
2002. This recommendation is based on interpretation* Correspondence: michael.maeng@ki.au.dk
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unless otherwise stated.of results of existing randomized clinical trials [1,2]. In
such trials, we expect adherence to treatment to be high
owing to patient selection, trial-related follow-up, and
cost-free provision of the platelet inhibitor. Adherence
to DAPT in real-world settings is most likely lower than
in these randomized trials. Assessment of adherence
levels and risks associated with discontinuation of DAPT
within the first year after coronary stent implantation is
needed in real-world settings.
Danish medical registries allow validated monitoring of
coronary interventions, prescription redemption, and
clinical outcomes [4-9]. Based on data from these registries,
we report rates of discontinuation of clopidogrel treatment
after coronary drug-eluting stent (DES) implantation and
assess the risk of associated adverse events.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Thim et al. BMC Cardiovascular Disorders 2014, 14:100 Page 2 of 8
http://www.biomedcentral.com/1471-2261/14/100Methods
According to the Central Denmark Region Committees on
Health Research Ethics, this study could be conducted
without an approval from the Committees.
Setting
We conducted this population-based cohort study, retro-
spectively, using medical registries in Western Denmark,
which has approximately three million inhabitants (55% of
the Danish population). The Danish National Health
Service provides universal tax-supported health care,
guaranteeing unfettered access to general practitioners and
hospitals. Costs of prescription medications, including
clopidogrel, are partially reimbursed. Accurate and un-
ambiguous linkage of data from all registries at the indivi-
dual level is possible in Denmark using the unique central
personal registry number assigned to every Danish citizen
at birth or upon immigration [9].
Patients and procedures
We used the Western Denmark Heart Registry (WDHR)
[10] to identify all PCI procedures performed between 1
January 2003 and 30 June 2005 [11-13]. For each patient,
the first PCI procedure with implantation of one or
more coronary DES during the inclusion period was
defined as the “index PCI procedure” and the date of
that procedure as the “index date”. Patients treated with
balloon angioplasty without stenting or with bare metal
stents alone were excluded. Only first-generation DES, i.e.,
sirolimus-eluting (SES) (Cypher, Cordis Corp., Johnson &
Johnson, Warren, New Jersey) and paclitaxel-eluting stents
(PES) (Taxus, Boston Scientific, Nattick, Massachusetts)
were in use during the inclusion period.
The cardiac intervention centers in Western Denmark
each perform more than 1,200 PCI procedures per year.
The interventions were performed according to current
standards including selection of interventional strategy
(e.g., pre- or post-dilatation, choice of stent, direct stenting,
and administration of periprocedural glycoprotein IIb/IIIa
inhibitors).
Patient characteristics
We obtained information from Danish National Registry
of Patients on potential confounders (diabetes and
hypertension) between 1977 and the index date [5]. To
ensure complete identification of patients with diabetes,
we also searched the Danish National Prescription Data-
base for any use of antidiabetic drugs among study par-
ticipants since 1994 [14]. From the WDHR, we retrieved
procedure data, including date of index PCI, indication
for PCI (ST-segment elevation myocardial infarction
(MI), non-ST-segment elevation myocardial infarction
MI or unstable angina pectoris, or stable angina pec-
toris), number of treated arteries (1, 2, or 3 or more),number of implanted stents (1, 2, or 3 or more), lesion
type (A, B1, B2, or C), and stent type.Medication use
We used the Danish National Prescription Database to
identify all redeemed prescriptions for clopidogrel
[14]. Clopidogrel is available only by prescription in
Denmark.
The recommended daily maintenance dose of clopidogrel
for secondary prevention of ischemic vascular events is
75 mg (one tablet) daily for 12 months following PCI. Thus,
for study purposes, the number of days supplied from a
redeemed clopidogrel prescription corresponded to the
number of tablets in the package. We computed the num-
ber of days exposed by adding 14 days to the number of
days supplied. This buffer allowed for a 14-day gap to occur
between redeemed prescriptions before a patient was
considered to have discontinued clopidogrel. This method
is well-established [15-17] and a 14-day gap has been used
in previous studies [18].
We also identified redeemed prescriptions for aspirin,
other nonselective non-steroidal anti-inflammatory drugs,
selective cyclooxygenase-2 inhibitors, proton pump inhibi-
tors, calcium channel blockers, statins, vitamin K antago-
nists, and systemic glucocorticoids.Major adverse events
In line with the recommended duration of clopidogrel
treatment, we recorded occurrence of major adverse car-
diovascular events (MACE) during 12 months after the
index date. We defined MACE as the first occurrence of
cardiac death, myocardial infarction MI, or definite stent
thrombosis (ST). A committee of cardiac specialists,
blinded to the history of medication use, reviewed rele-
vant medical records to determine occurrence of definite
stent thrombosis ST and cardiac death.Cardiac death
We obtained data on all-cause mortality from the Danish
Civil Registration System [9]. The committee of cardiac
specialists reviewed original death certificates obtained
from the National Registry of Causes of Deaths [6]. Deaths
were classified as either cardiac or non-cardiac based on
the underlying cause recorded on the death certificates. We
defined cardiac death as known cardiac death, unwitnessed
death, or death from unknown causes.Myocardial infarction (MI)
We used the Danish National Registry of Patients to
identify hospital admissions with MI as discharge diag-
nosis [5].
Table 1 Patient and procedure characteristics
N = 4,154* %
Female 1,127 27.1
Age group (years)
<60 1,659 39.9
60-70 1,316 31.7
70+ 1,179 28.4
Medication use†
Clopidogrel 3,931 94.6
Proton pump inhibitors 955 23.0
Aspirin 3,718 89.5
Vitamin K antagonists 301 7.2
Nonselective NSAIDs 509 12.3
COX-2 inhibitors 388 9.3
Oral glucocorticoids 309 7.4
Calcium channel blockers 1,153 27.8
Statins 3,606 86.8
Comorbidities‡
Diabetes 586 14.1
Hypertension 178 4.3
Year of study entry
2003 847 20.4
2004 1,836 44.2
2005 1,471 35.4
PCI Indication
STEMI 844 20.3
UAP/NSTEMI 1,277 30.7
SAP 1,902 45.8
Other 131 3.2
Number of treated arteries§
1 2,877 69.3
2 1,057 25.4
3 212 5.1
Number of Stents§
1 3,301 79.5
2 631 15.2
3+ 208 5.0
Lesion Type§║
A 898 21.6
B 2,165 52.1
C 1,091 26.3
*Drug-eluting stents only (n = 3,548) and combination of drug-eluting stents and
bare metal stents (n = 606).
†Any prescription redemption during follow up.
‡Registered between 1977 and the index PCI date.
§Data were not available on number of treated arteries for 112 patients, on the
number of stents for 62 patients, and on lesion type for 6 patients.
║Lesion classification: A = non-complicated, length <10 mm; B = irregular, length
10–20 mm; C = irregular, side branch, 90 degrees, chronic occlusion, length 20 mm.
Abbreviations: COX cyclooxygenase, NSAIDs nonsteroidal anti-inflammatory
drugs, PCI percutaneous coronary intervention, STEMI ST-segment elevation
myocardial infarction, SAP stable angina pectoris, UAP unstable angina
pectoris, NSTEMI non-ST-segment elevation myocardial infarction.
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Based on review of medical records and angiograms, the
committee of cardiac specialists adjudicated the occur-
rence of definite ST according to Academic Research
Consortium definitions [19].
Statistical analysis
We characterized the patients using medical, procedural,
and demographic variables and followed all patients
from their index date until date of death or completion
of 12 months of follow up.
To describe the pattern of clopidogrel compliance, we
first calculated the proportion of patients still alive who
had prescription coverage for clopidogrel on each day of
follow up. We also calculated the mean and median pro-
portion of days within the first year after stent implant-
ation with prescription coverage for clopidogrel among
patients not experiencing MACE.
We then estimated the effect of discontinuing clopido-
grel treatment. We defined discontinuation as a gap
between prescription redemptions of more than 14 days.
We estimated the effect separately according to the time
of discontinuation, i.e., within the first 3 months (day 1
through 91), 3 to 6 months (day 92 through 182), or 6 to
12 months (day 183 through 365) after the index PCI
procedure. We estimated hazard ratios using a Cox pro-
portional hazards regression model. Hazard ratios were
adjusted for potential confounders (age, gender, year of
index PCI, indication for PCI, comorbidity level (using
Charlson Comorbidity Index scores)) and time-varying
use (calculated from the number of days exposed) of as-
pirin, other nonselective non-steroidal anti-inflammatory
drugs, and proton pump inhibitors. Patients entered the
study at the time of their first clopidogrel prescription
redemption after the index date (delayed entry). Patients
contributed to time at risk as current users of clopido-
grel as long as they had prescription coverage for clopi-
dogrel. From the time point of discontinuation, patients
contributed time at risk according to their time window
of discontinuation [15-17].
Results
The study included 4,154 patients treated with DES. Of
these, 2,570 patients were treated with implantation of
SES, 1,525 patients with PES, and 59 patients with
SES and PES. Patient and procedure characteristics are
shown in Table 1.
Rates of clopidogrel treatment discontinuation
In Figure 1, the proportion of patients with prescription
coverage for clopidogrel on each day of follow up is plot-
ted against time since the index PCI procedure date.
There was a drop in prescription coverage between 3
and 4 months after the index PCI procedure, and again
Figure 1 Proportion of patients covered by a prescription for
clopidogrel on each day during follow up.
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patients who never redeemed a prescription for clopido-
grel during follow up was 5.4%. Among the 3,815 event-
free survivors, the mean percentage of days covered by a
clopidogrel prescription was 81% (median: 96%).
Risk associated with clopidogrel treatment
discontinuation
Figure 2 shows the cumulative incidence of MACE dur-
ing the first year after the index PCI procedure. The risk
of MACE increased most within the first 2 weeks following
the procedure (approximately 3%) and then increased more
gradually during the remainder of the one-year study
period (overall 1-year risk was approximately 6%). Figure 3Figure 2 Cumulative incidence of major adverse cardiac events (MA
and definite stent thrombosis.shows the cumulative incidence of MACE over time start-
ing from the time-point of discontinuation. The increase in
cumulative risk of MACE was highest within the first
2 months following discontinuation.
Table 2 shows crude and adjusted hazard ratios for
discontinuation of clopidogrel treatment. The 1-year cumu-
lative MACE rate among patients covered by clopidogrel
prescriptions for the full year was 3.9%. Discontinuation of
clopidogrel within the first 3 months after PCI was associ-
ated with an increased rate of MACE (approximately 2-
fold) and cardiac death (almost 5-fold). The risk estimates
for the individual components of the combined outcome
were also increased, with wider confidence intervals due to
fewer events. Definite ST as an individual outcome was too
rare within the first 3 months to allow for statistical infer-
ence. When discontinuation of clopidogrel occurred later
than 3 months following PCI, differences in rates were not
statistically significant, however, the hazard ratios sug-
gested that risk of MACE was increased by approxi-
mately 30%, cardiac death by 80%, and MI by 10%
when clopidogrel was discontinued later than 3 months
following PCI. ST was rare and clopidogrel discontinu-
ation between 3-6 months was associated with a non-
significant 7-fold higher risk of ST, corresponding to
an almost 3% risk of ST in this subgroup.
Patients who never redeemed a single clopidogrel pre-
scription were not included in the analyses described
above. Among these patients, the cumulative incidence
of MACE was 48% within one week, 59% within one
month, 61% within 3 months, and 63% within one year
following PCI. Thus, these patients experienced very
high early MACE rates, but rates after 3 months wereCE). MACE is a composite of cardiac death, myocardial infarction,
Figure 3 Cumulative incidence of major adverse cardiac events (MACE) following discontinuation of clopidogrel. MACE is a composite of
cardiac death, myocardial infarction, and definite stent thrombosis.
Table 2 Hazard ratios (HRs) for discontinuation of
clopidogrel treatment
Time following
DES implantation
HR (95% CI) Adjusted HR
(95% CI)
MACE 0-3 months 2.48 (1.30-4.71) 2.06 (1.08-3.93)
3-6 months 1.26 (0.68-2.33) 1.29 (0.70-2.41)
6-12 months 1.26 (0.53-2.99) 1.29 (0.54-3.07)
Cardiac death 0-3 months 6.84 (3.06-15.3) 4.80 (2.13-10.8)
3-6 months 1.95 (0.72-5.30) 1.85 (0.68-5.04)
6-12 months 1.65 (0.42-6.46) 1.74 (0.45-6.78)
Myocardial infarction 0-3 months 2.05 (0.93-4.53) 1.84 (0.83-4.09)
3-6 months 1.08 (0.51-2.28) 1.14 (0.54-2.43)
6-12 months 1.09 (0.36-3.35) 1.09 (0.35-3.34)
Definite stent
thrombosis
0-3 months - -
3-6 months 6.04 (0.52-70.2) 7.14 (0.61-83.7)
6-12 months - -
MACE is a composite of cardiac death, myocardial infarction, and definite
stent thrombosis.
Abbreviations: HR hazard ratio, CI confidence interval.
Hazard ratios were adjusted for age, gender, year of index PCI, PCI indication,
comorbidity level (using Charlson Comorbidity Index scores), and time-varying
use (calculated from the number of days exposed) of aspirin, other NSAIDs,
and proton pump inhibitors.
0-3 months = day 1 through 91; 3 to 6 months = day 92 through 182; 6 to
12 months = day 183 through 365.
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shown in Figure 2. Early events, such as in-hospital
death, may have prevented some of these patients from
ever redeeming a clopidogrel prescription.
Discussion
Our main findings from this study of 4,154 consecutive
real-world patients treated with first-generation DES are
that discontinuation of clopidogrel was common and
that discontinuation within the first 3 months after stent
implantation was associated with an approximately two-
fold increase in risk of MACE and an almost 5-fold
increase in risk of cardiac death.
Registry data
In cohort studies, premature clopidogrel discontinuation
after DES implantation is fairly common. Data are con-
flicting on whether discontinuation, at least beyond the
first 4-6 months, is associated with adverse events. These
conflicting results may reflect major differences among
these studies, including data acquisition, study design,
and statistical approach.
Clopidogrel treatment is generally recommended for
12 months after DES implantation. Rates of clopidogrel
discontinuation within these 12 months have been re-
ported to be 14% within the first month [20], 28% by
6 months [18], and 4%-38% by 12 months [21-26]. The
discontinuation rate reported in our study is similar in
magnitude to that of most other reports [18,20-22,25,26].
The timing of clopidogrel discontinuation within the
first year appears to be of major importance. Patients
discontinuing DAPT within 7, 8-30, or >30 days afterPCI due to non-compliance or bleeding had a 7-fold, 2-
fold, and 1.3-fold higher risk of MACE, respectively [26].
Among patients with MI, clopidogrel discontinuation
within the first month after coronary stent implantation
has been associated with a 9-fold increased risk of death
by 12 months [20]. Discontinuation within the first year,
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with adverse events [21]. Based on a landmark approach,
3 studies evaluating event-free patients after 4-6-months
of follow-up found that continued use of P2Y12 antago-
nists did not reduce the risk of adverse events [22,27,28],
while 2 other studies showed that it reduced the risk
[21,29]. Regional differences, particularly socio-economic
factors affecting compliance, may explain this discrepancy
in part. In addition, the landmark approach is limited by
the healthy survivor effect. Further, in all the studies
described above, information about clopidogrel adherence
relied on self-reports by patients or their relatives during
visits or telephone interviews. Such contacts likely influ-
enced clopidogrel compliance positively, making the data
subject to non-differential misclassification bias.
A unique feature of the current study is the linkage of
Danish national registries, thereby avoiding the mis-
classification bias associated with self-reporting. Only a
single study previously linked data from a national pre-
scription registry with clinical outcomes to assess the
impact of premature clopidogrel discontinuation after
DES implantation [18]. Similar to our findings, 28% of
study patients discontinued clopidogrel within 6 months
after their PCI procedure, and patients who discontinued
clopidogrel within the first 6 months had a 2-fold higher
risk of death at 12 months. In contrast to this earlier
study, the current study included patients younger than
65 years, examined occurrence of MI and ST, and
assessed the risk of discontinuing clopidogrel for 3 time
intervals.
Individual variation in platelet response to clopidogrel
is a subject of debate, providing some of the rationale
behind development of newer and currently more
expensive platelet inhibitors, such as ticagrelor and pra-
sugrel [30,31]. While the clinical benefits of the newer
platelet inhibitors are small compared to clopidogrel,
they become significant in large populations of patients
with acute coronary syndromes. At the same time, the
impact of compliance to DAPT, at least within the first
3 months after PCI, is major. Therefore, approaches to
decrease rates of early DAPT discontinuation should
be a major focus of future research and daily clinical
practice.
Randomized trial data
Results from 2 on-going clinical trials are awaited
[32,33]. Recently, it was reported that 3 months was
non-inferior to 12 months of of DAPT after stent im-
plantation [34]. The balance between reduction of ische-
mic events and the risk of bleeding may favor DAPT for
3 to 6 months after DES implantation and extending
DAPT further might be associated with a risk of bleed-
ing outweighing the benefit [35,36]. However, it has been
found that DAPT for 1 year was superior to a 1-monthregimen [2]. Recently, 4 randomized studies have been
conducted, in which event-free patients were rando-
mized to 3 [37], 6 [38,39] or 12 [40] months versus
prolonged DAPT following PCI. All 4 trials reported no
benefit of prolonged clopidogrel treatment [35,37-40].
Importantly, these randomized data, agree with our
registry data based on consecutive real-world patients.
Limitations
The strength of this study lies in its use of population-
based registries with complete follow-up. However, a
number of limitations should be acknowledged. First,
some patients may have redeemed their prescriptions
without taking all or any of the tablets. Moreover, tem-
porary discontinuations < 14 days were not detected.
However, others have shown that such short discontinu-
ations do not affect outcomes [24]. Second, aspirin use
could not be completely assessed in this study, as aspirin
is available without a prescription. This limitation may
be relevant at least for ST [22]. However, low-dose as-
pirin used for secondary prevention of cardiovascular
disease generally is prescribed by physicians because
prescription costs are partly reimbursed through the na-
tional health insurance program. Third, despite adjust-
ment for comorbidities, we cannot exclude residual
confounding. Fourth, it has been reported that the posi-
tive effect of compliance with medication regimens is
lower than estimated from observational studies [41].
The true protective effect of clopidogrel in routine clin-
ical care patients thus may be lower than estimated here.
Fifth, the decline in adherence to clopidogrel treatment
after 3-4 months and 6 months after the index PCI pro-
cedure was likely caused by a combination of medical
decisions for discontinuation and patients’ lack of com-
pliance [20,23,26]. Sixth, the results obtained are limited
to the 2 first-generation DES. As newer DES are consi-
dered safer than the first generation DES [42], the im-
pact of discontinuation of prolonged DAPT is likely to
be lower with newer stents.
Conclusion
Discontinuation of clopidogrel was associated with an
increased rate of MACE among patients treated with
DES. The increase was statistically significant within the
first 3 months after DES implantation but not after 3 to
12 months.
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